38th week of 2012 patent applcation highlights part 38 |
Patent application number | Title | Published |
20120237434 | Split Flow Contactor - Systems and methods for contacting a liquid, gas, and/or a multi-phase mixture with particulate solids. The system can include a body having a first head and a second head disposed thereon. Two or more discrete fixed beds can be disposed across a cross-section of the body. One or more unobstructed fluid flow paths can bypass each fixed bed, and one or more baffles can be disposed between the fixed beds. | 2012-09-20 |
20120237435 | Mass Production of Carbon Nanostructures - Carbon nanostructures are mass produced from graphite. In particularly preferred aspects, graphene is thermo-chemically derived from graphite and used in numerous compositions. In further preferred aspects, the graphene is re-shaped to form other nanostructures, including nanofractals, optionally branched open-ended SWNT, nanoloops, and nanoonions. | 2012-09-20 |
20120237436 | Catalyst For The Growth Of Carbon Single-Walled Nanotubes - Methods and processes for synthesizing single-wall carbon nanotubes are provided. A carbon precursor gas is contacted with metal catalysts deposited on a support material. The metal catalysts are preferably nanoparticles having diameters less than about 3 nm. The reaction temperature is selected such that it is near the eutectic point of the mixture of metal catalyst particles and carbon. Further, the rate at which hydrocarbons are fed into the reactor is equivalent to the rate at which the hydrocarbons react for given synthesis temperature. The methods produce carbon single-walled nanotubes having longer lengths. | 2012-09-20 |
20120237437 | CARBON MATERIAL AND METHOD OF MANUFACTURING THE SAME - A carbon material and a method of manufacturing the carbon material are provided that can improve hardness and physical properties while fully gaining the benefit of SPS method, which makes it possible to obtain a dense carbon material with very short time. | 2012-09-20 |
20120237438 | Adaptive Control System for a Sulfur Recovery Process - Control of a process for producing free sulfur from hydrogen sulfide is accomplished by manipulating the flow rate of a feed stream containing oxygen to a furnace in such a manner that a desired proportion of the hydrogen sulfide fed to the furnace is converted to sulfur dioxide. Combustion of hydrogen sulfide is precisely controlled by the proposed system to maintain the hydrogen sulfide and sulfur dioxide concentrations in the tail gas at acceptable levels to minimize the environmental pollution. | 2012-09-20 |
20120237439 | PROCESS FOR PREPARING AN ALUMINA WITH CONTROLLED MESOPOROSITY - A process for preparing a mesoporous alumina is described, comprising the following steps:
| 2012-09-20 |
20120237440 | METHOD FOR PRODUCING HYDROGEN BY MEANS OF THERMOCHEMICAL WATER-SPLITTING, AND DEVICE FOR PRODUCING HYDROGEN - The disclosed method for producing hydrogen by means of thermochemical water-splitting can efficiently use solar energy obtained by means of a beam-down typed light collecting system. Further disclosed is a device for producing hydrogen. While circulating within a reactor ( | 2012-09-20 |
20120237441 | ENHANCED B CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY - Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent, including a chemotherapeutic agent, radioactive isotope, cytotoxic antibody, immunoconjugate, ligand conjugate, immunosuppressant, cell growth regulator and/or inhibitor, toxin, or mixtures thereof, including agents that disrupt the cytoskeleton of B cells, particularly vinca alkaloids or colchicine. | 2012-09-20 |
20120237442 | Design and Construction of Novel Multivalent Antibodies - The present invention concerns compositions and use of multivalent and/or multispecific antibodies or immunoconjugates, preferably made by the dock-and-lock technique. The antibodies or immunoconjugates may comprise a first and second polypeptide, each comprising V | 2012-09-20 |
20120237443 | FUNCTIONALIZING IMPLANTABLE DEVICES WITH A POLY (DIOL CITRATE) POLYMER - The present invention is directed to a novel poly (diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells. | 2012-09-20 |
20120237444 | IODINE RADIOLABELLING METHOD - The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using the radioiodinated BTMs. | 2012-09-20 |
20120237445 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID - Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5. | 2012-09-20 |
20120237446 | Compounds for binding and imaging amyloid plaques and their use - The present invention relates to novel compounds (3-aminopropen-1-ones) useful for binding and imaging beta amyloid deposits and their use in detecting or treating Alzheimer's disease and amyloidosis. | 2012-09-20 |
20120237447 | STAR POLYMER NANOSHELLS AND METHODS OF PREPARATION THEREOF - A nanoshell is disclosed, comprising a star polymer occlusion complex comprising i) an amphiphilic unimolecular star polymer having a crosslinked core covalently linked to 6 or more independent polymer arms, and ii) a cargo material occluded in the star polymer; and a shell comprising an inorganic material in contact with a peripheral surface of the star polymer occlusion complex. | 2012-09-20 |
20120237448 | SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME - Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM). | 2012-09-20 |
20120237449 | METHODS FOR TREATING NEURAL CELL SWELLING - A composition comprising a novel Ca | 2012-09-20 |
20120237450 | Stabilized Ultrasound Contrast Agent - Provided is a particle-stabilized ultrasound contrast agentn (UCA) and methods of preparing same. Also provided is a method for preparing a lyoprotected UCA, a freeze-dried lyoprotected UCA, and a reconstituted freeze-dried lyoprotected UCA. | 2012-09-20 |
20120237451 | NOVEL MOLECULAR BEACONS - The invention provides novel compositions and methods for the detection of a target molecule. Specifically, the invention provides a bimolecular beacon composition comprising two nucleic acid molecules, and methods thereof. One of the nucleic acid molecule is operably linked to a reporter detectable label and the other nucleic acid molecule is operably linked to a reference detectable label and a quencher. In some embodiments, at least one of the nucleic acid molecules comprises a single stranded overhang. | 2012-09-20 |
20120237452 | Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound And Process Therefor - The present invention relates to a stable antiseptic solution comprising: a di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof, wherein said di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to a process for preparing said antiseptic solution. | 2012-09-20 |
20120237453 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM - This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical, therapeutic and cosmetic compositions, comprising an active agent, having a sensation or sensation modifying affect on a body surface, upon application. More particularly, the invention relates to foamable compositions comprising: (a) a foamable carrier; (b) at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; stimulating or refreshing agent; or mixtures thereof and (c) a propellant at a concentration of about 3% to about 45% by weight of the total composition. The foamable carrier can be an emollient emulsion foamable vehicle, a foamable gel vehicle and can also be a substantially non aqueous foamable vehicle. | 2012-09-20 |
20120237454 | Means and Methods for Preventing and/or Treating Caries - The present invention relates to a microorganism belonging to the group of lactic acid bacteria capable of specifically binding to | 2012-09-20 |
20120237455 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZIZYPHUS JOAZEIRO AND RELATED METHODS - Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same. | 2012-09-20 |
20120237456 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS - Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same. | 2012-09-20 |
20120237457 | ANTI-BACTERIAL ORAL CARE COMPOSITION AND METHOD FOR PRODUCING THE SAME - An anti-bacterial oral care composition and method for producing the same are disclosed. The composition comprises chitosan, organic acid, bioflavonoids and xylitol that are mixed together and can effectively inhibit the growth of bacteria in oral cavity, such as 99.9% of staphylococcus aureus, 99.9% of streptococcus mutans, 99.9% of candida albicans, thus reducing the occurrence of decayed tooth. Furthermore, no chemical preservative and anti-bacterial agent are added in the composition, reducing the damage to the oral mucosa and the health of the user. | 2012-09-20 |
20120237458 | HYDROGEL PARTICLES - Hydrogel particles include: (A) a water-insoluble complex containing catechins; (B) a compound which forms chelate together with divalent or trivalent metal ions; (C) a divalent or trivalent metal salt; (D) a gel-forming agent; and (E) water. | 2012-09-20 |
20120237459 | Methods for Improving the appearance of hyperpigmented skin using a synergistic composition comprising banyan tree, lotus, and clover serum fractions - A method of improving the appearance of a hyperpigmented spot may comprise the step of applying a composition comprising an effective amount of banyan tree serum fraction, lotus serum fraction, and clover serum fraction to a hyperpigmented spot on a skin surface, wherein the composition is applied for a period of time sufficient to improve the appearance of the hyperpigmented spot. The method may include the step of identifying a hyperpigmented spot on a facial skin surface. Other methods as disclosed include a method for improving the appearance of post-inflammatory hyperpigmentation. | 2012-09-20 |
20120237460 | Methods for Improving the Appearance of Aging Skin Using a Composition Comprising Banyan Tree, Lotus, and Clover Serum Fractions - A method of improving the appearance of aging skin may comprise the step of applying a composition comprising an effective amount of banyan tree serum fraction, lotus serum fraction, and clover serum fraction to a sign of aging on a skin surface, wherein the composition is applied for a period of time sufficient to improve the appearance of the aging skin. The method may include the step of identifying a sign of aging on a facial skin surface. | 2012-09-20 |
20120237461 | SKIN COMPOSITIONS AND METHODS OF USE THEREOF - Provided are therapeutic formulations and methods of use thereof. | 2012-09-20 |
20120237462 | Aqueous Composition For Cosmetics And Cosmetic Including the Same - An aqueous composition, for alleviating at least one problem that conventional aqueous cosmetic compositions, includes (A) at least one selected from the group consisting of a cross-linked product of a hydroxyalkyl modified starch with a carbon number of 2 to 5, a cross-linked product of a hydroxyalkyl modified starch with a carbon number of 2 to 5 and an acyl modified starch with a carbon number of 2 to 18 and a cross-linked product of an acyl modified starch with a carbon number of 2 to 18; and (B) a water-soluble polymer material. When the water-soluble polymer material (B) is an association type poly(meth)acrylate polymer, a nonionic or cationic cellulose polymer, a poly(meth)acrylic acid polymer or xanthan gum, the aqueous composition exhibits excellent viscosity increase ratio and temporal stability. | 2012-09-20 |
20120237463 | COSMETIC EMULSIONS CONTAINING UNCOATED SILICONE ELASTOMERS AND NON SILICONE TREATED PIGMENTS - Disclosed are cosmetic compositions in the form of an emulsion that contain an uncoated silicone elastomer, a solvent for the elastomer, a non-silicone treated pigment and an emulsifier, methods of making the compositions, and methods of applying the compositions to a keratinous substrate or tissue. | 2012-09-20 |
20120237464 | HYDROPHILICALLY-MODIFIED SILICONE COMPOSITIONS - In various embodiments, provided are hydrophilically-modified silicone compositions comprising substantially spherical elastomeric microparticles, methods of making such compositions, and silicone pastes, personal care, and healthcare products comprising such silicone compositions. | 2012-09-20 |
20120237465 | Hydrolytically Stable Multi-Purpose Polymer - The present invention relates to compositions containing hydrolytically stable multi-purpose polymers that are polymerized from a monomer mixture comprising: at least one amino-substituted meth(acrylate) (ASMA) monomer or salt thereof; and at least one nonionic vinyl (NIV) monomer, wherein the monomer mixture optionally comprises one or more of at least one vinyl associative (VA) monomer; at least one vinyl surfactant (VS) monomer; and/or at least one polymerizable silicone macromer (PSM) and wherein the monomer mixture further optionally comprises one or more of at least one crosslinking (XL) monomer; at least one chain transfer agent (CTA); and/or at least one polymeric stabilizer. The multi-purpose polymers of the present invention can also be prepared from monomer mixtures containing chain transfer agents or other functional components commonly utilized in polymerization processes. | 2012-09-20 |
20120237466 | PHOTO-FILTERING COMPOSITION FOR HAIR AND SCALP - An all natural topically applied broad spectrum photo-filtering composition for both styling of hair and protecting hair and scalp from ultraviolet radiation is comprised of natural oils, vitamins and amino acids having UV absorption properties which in combination with at least one inorganic particulate selected from the group consisting of titanium dioxide arid zinc oxide afford broad spectrum photo protection of both hair and scalp across the UV and IRA spectrum. Combining the above with bees wax, glycerin, gelatin and wafer, produces an emulsified gel suitable for styling hair while simultaneously protecting the hair and scalp from damaging UV and IR rays. | 2012-09-20 |
20120237467 | Lip Cosmetics - The present invention provides a lip cosmetic that has excellent secondary adhesion resistance effect immediately after the application and is excellent in gloss durability and stability. The lip cosmetic of the present invention is characterized by comprising the following components (a) to (d): | 2012-09-20 |
20120237468 | CONDITIONING COMPOSITION COMPRISING AMIDOAMINE AND LACTIC ACID - Conditioning composition comprising a quaternary conditioning surfactant, an acid neutralized amidoamine surfactant of general formula: R1-C(O)-NH-R2-N(R3)(R4) wherein R1 is a fatty acid chain with from 12 to 22 carbon atoms, R2 is an alkylene group containing from one to 4 carbon atoms and R3 and R4 are, independently, an alkyl group having from one to four carbon atoms and from 0.45 to 4% wt. of the composition lactic acid. | 2012-09-20 |
20120237469 | MALODOR NEUTRALIZING COMPOSITIONS COMPRISING BORNYL ACETATE OR ISOBORNYL ACETATE - Composition comprising bornyl or isobornyl acetate and certain acids are effective for reducing malodors. The acids have the formula R—COOH in which R is C | 2012-09-20 |
20120237470 | AMIDO-AMINE POLYMER COMPOSITIONS - Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans. | 2012-09-20 |
20120237471 | Poly(CPP-SA) Anhydride As A Reactive Barrier Matrix Against Percutaneous Absorption Of Toxic Chemicals - The present invention relates to a protective agent suitable to protect the human skin against toxic materials, particularly against chemicals with nucleophilic sites. The active moiety is a polyanhydride derivative. The active transdermal retardant offers a barrier property and chemically and/or physically reacts with harmful chemicals to decrease percutaneous absorption. In the preferred embodiments, polyanhydride in its low molecular weight form reduced flux of nicotine and nitrofurazone significantly. Additionally, polyanhydride in its high molecular weight form prevented nicotine absorption and decreased nitrofurazone permeation dramatically. Moreover, the polyanhydride in its high molecular weight form reduced nitroglycerin flux to a lesser extent. | 2012-09-20 |
20120237472 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES USING IMMUNOMODULATORY AGENTS - The present invention provides compositions and methods for treating and/or preventing an autoimmune disease comprising administering to a subject in need thereof an effective amount of cyclophosphamide and/or a cyclophosphamide derivative in combination with an additional immunomodulatory agent. | 2012-09-20 |
20120237473 | Compositions And Methods For Cell Based Retinal Therapies - The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation. | 2012-09-20 |
20120237474 | FLUORINATED DIARYL UREA DERIVATIVES - This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases. | 2012-09-20 |
20120237475 | Novel Inhibitors - Novel heterocyclic derivatives of formula (I): | 2012-09-20 |
20120237476 | Pharmaceutical Compositions for Sustained Release Delivery of Peptides - The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which are dissolved or dispersed in a biocompatible, water-soluble organic solvent. This invention also provides related compositions and methods. | 2012-09-20 |
20120237477 | METHODS AND COMPOSITIONS FOR TREATING POST-MYOCARDIAL INFARCTION DAMAGE - Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area. | 2012-09-20 |
20120237478 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula IV, | 2012-09-20 |
20120237479 | METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN - The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time. | 2012-09-20 |
20120237480 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention relates to 2′-allene-substituted nucleoside derivatives of the general formula (I): | 2012-09-20 |
20120237481 | Incorporation of the B18R gene to enhance antitumor effect of virotherapy - The present invention relates to a novel composition and method to potentiate the antitumor effect of an oncolytic virus by providing for resistance against a host's innate interferon response. Particularly, a B18R gene is incorporated into an oncolytic virus. During treatment of a host with the modified oncolytic virus, the oncolytic virus retains its phenotype, and the host's innate immune response has a minimal affect on viral replication. | 2012-09-20 |
20120237482 | METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS BY MODULATION OF MICROGLIAL ACTIVATION - Methods for treatment of neurological disorders with respect to microglial activation are presented herein. Other examples and related pharmaceutical combinations and compositions are also described herein. | 2012-09-20 |
20120237483 | Oncolytic Virotherapy for Prevention of Tumor Recurrence - Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor. | 2012-09-20 |
20120237484 | Generation of Functional Basal Forebrain Cholinergic Neurons From Stem Cells - The present invention provides method, compositions, and systems for generating basal forebrain cholinergic neurons (BFCNs) using FGF8, SHH, LXH8, GBX1, or vectors encoding these ligands, as well as using such BFCNs to treat neurological disorders such as Alzheimer's disease. | 2012-09-20 |
20120237485 | Trabecular Meshwork Stem Cells - Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject. | 2012-09-20 |
20120237486 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 2012-09-20 |
20120237487 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 2012-09-20 |
20120237488 | LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER - A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis. | 2012-09-20 |
20120237489 | SUPPOSITORY FOR RECTAL, VAGINAL OR URETHRAL ADMINISTRATION CONTAINING A PROBIOTIC, AN ANTIBIOTIC AND AN UNSATURATED NON-ESTERIFIED FATTY ACID - A suppository is provided for rectal, vaginal or urethral administration. A method also is provided for the preparation of a suppository for rectal, vaginal or urethral administration. The method uses at least one unsaturated, non-esterified fatty acid in a composition containing a probiotic and an antibiotic. | 2012-09-20 |
20120237490 | SYSTEMS AND METHODS FOR AUTOLOGOUS BIOLOGICAL THERAPEUTICS - This disclosure describes systems, methods, and apparatus for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and/or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and/or volume. | 2012-09-20 |
20120237491 | PHAGE DERIVED ANTIMICROBIAL ACTIVITIES - The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. | 2012-09-20 |
20120237492 | TREATMENT OF SUBMENTAL FAT - This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin. | 2012-09-20 |
20120237493 | NUCLEIC ACIDS ENCODING A MUT-T DOMAIN-CONTAINING POLYPEPTIDE - The invention pertains to nucleic acids encoding a mutT domain-containing polypeptide, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing polypeptide and nucleic acids and agents that bind the foregoing polypeptide and nucleic acids. The invention also pertains to the identification of a novel mutT domain in human TrpC7, a polypeptide previously described as a putative calcium ion channel. Accordingly, the invention also pertains to methods and compositions for identifying agents useful in modulating mutT domain-mediated calcium or other ion transport in cells expressing a polypeptide comprising a mutT domain and a calcium or other ion channel. | 2012-09-20 |
20120237494 | Compositions Containing Zinc PCA And Anogeissus Extract - A topical composition comprising at least one extract from the | 2012-09-20 |
20120237495 | METHOD OF TREATMENT USING SOLUBILIZED PROTEIN COMPOSITION OBTAINED FROM EGGSHELL MEMBRANE - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 2012-09-20 |
20120237496 | PROTEASE VARIANTS - The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta. | 2012-09-20 |
20120237497 | COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASES - The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from | 2012-09-20 |
20120237498 | 4-1BB BINDING MOLECULES - The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 2012-09-20 |
20120237499 | Modulators of TDP-43 Mediated Toxicity and Methods of Use Thereof for Identifying Agents Having Efficacy for the Treatment and Prevention of Proteinopathies - Compositions and methods are disclosed for identifying agents useful for the treatment of proteinopathies. | 2012-09-20 |
20120237500 | SCD Fingerprints - This invention relates to methods of testing, diagnosing, monitoring, prognostically stratifying and classifying disease, disorders and other medical conditions and physiological states through the detection and analysis of soluble CD antigens in a body fluid sample. | 2012-09-20 |
20120237501 | Anti-HIV Peptides and Methods of Use Thereof - Anti-HIV peptides and methods of use are provided. In particular, these HIV inhibitory peptides are discovered based on the Antimicrobial Peptide Database. | 2012-09-20 |
20120237502 | METHOD FOR TREATING BREAST CANCER AND OVARIAN CANCER - The present invention relates to a method for the prevention or treatment of certain breast cancers or ovarian cancer comprising administering to a patient in need thereof of a therapeutically effective amount of a 17,20-lyase inhibitor, wherein the breast cancer or ovarian cancer is estrogen receptor (ER) negative. | 2012-09-20 |
20120237503 | Screening Method and Therapy with Agonists of DDAH I - The present invention derives from the finding that decreased levels of DDAH I are associated with increased portal pressure and that by increasing DDAH I levels in vivo, portal pressure may be reduced. Accordingly, the invention provides methods for reducing portal blood pressure comprising administering to a subject in need thereof an agonist of DDAH I. | 2012-09-20 |
20120237504 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND FIBROSIS - The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject. | 2012-09-20 |
20120237505 | TARGETING OF CD8+ T-LYMPHOCYTES TO TREAT NEURODEGENERATIVE DISEASES - Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells. | 2012-09-20 |
20120237506 | Antigen Binding Proteins - The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof. | 2012-09-20 |
20120237507 | Monovalent Antigen Binding Proteins - The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2012-09-20 |
20120237508 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS - The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease. | 2012-09-20 |
20120237509 | Anti-Mesothelin Antibodies - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments. | 2012-09-20 |
20120237510 | Anti-NKG2A Antibodies and Uses Thereof - Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described. | 2012-09-20 |
20120237511 | FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES - Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent. | 2012-09-20 |
20120237512 | Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 2012-09-20 |
20120237513 | Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 2012-09-20 |
20120237514 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF - The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided. | 2012-09-20 |
20120237515 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT - Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH. | 2012-09-20 |
20120237516 | COMPOSITIONS AND METHODS RELATING TO ANTI-IGF-1 RECEPTOR ANTIBODIES - The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 2012-09-20 |
20120237517 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 2012-09-20 |
20120237518 | ANTI-TROP-2 ANTIBODY - The present invention relates to a monoclonal antibody or an antibody fragment thereof, which binds to the extracellular region of human Trop-2 with high affinity and exhibits high ADCC activity and high antitumor activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent or a diagnostic agent using the antibody fragment thereof. | 2012-09-20 |
20120237519 | PESTVIRUS SPECIES - The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further relates to detection methods, vaccine therapeutics, and diagnostic methods using the PMC virus or gene/protein sequences derived therefrom. | 2012-09-20 |
20120237520 | BORIS ISOFORMS AND METHODS OF DETECTING AND TREATING DISEASE - A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same. | 2012-09-20 |
20120237521 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH - This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse. | 2012-09-20 |
20120237522 | ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY - Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer. | 2012-09-20 |
20120237523 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes. | 2012-09-20 |
20120237524 | MET INHIBITORS FOR ENHANCING RADIOTHERAPY EFFICACY - Met inhibitor and/or nucleotide sequence encoding a Met inhibitor for use in the treatment of patients suffering from a cancer for reducing and/or abrogating patients' resistance to radiotherapy, wherein the Met inhibitor is selected among: i) an anti-Met monoclonal antibody, ii) a genetically engineered antibody containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, and iii) a fragment of (i) or (ii) containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, or combinations thereof. | 2012-09-20 |
20120237525 | COMBINATION PREPARATION INCLUDING A CYTOKINE ANTAGONIST AND CORTICOSTEROID - The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated. | 2012-09-20 |
20120237526 | BACE1 INHIBITORY ANTIBODIES - The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease. | 2012-09-20 |
20120237527 | Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus - Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated. | 2012-09-20 |
20120237528 | Human Tissue Factor Antibody and Uses Thereof - The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs. | 2012-09-20 |
20120237529 | DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 2012-09-20 |
20120237530 | INTEGRIN ALPHA 8-BETA 1-SPECIFIC MONOCLONAL ANTIBODY - [Object] To obtain an anti-integrin α8β1 antibody which binds to integrin α8β1 derived from mammals of different species. Also, to obtain an anti-integrin α8β1 antibody which inhibits binding between integrin α8β1 and its ligand. | 2012-09-20 |
20120237531 | TOPOISOMERASE INHIBITORS - The invention provides compounds of formula I: (I) wherein A, B, W, Y, Z, R | 2012-09-20 |
20120237532 | PHARMACEUTICAL FORMULATION CONTAINING IMMUNOGLOBULIN - A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein; wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs); and wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs. | 2012-09-20 |
20120237533 | Compositions and Methods for Inducing Apoptosis in Prostate Cancer Cells - Compositions and methods for inhibiting the growth of cancer cells, particularly prostate cancer cells are disclosed. | 2012-09-20 |